Event held at Fort
Worth Fire Department in partnership with Front Line Mobile
Health
NEW
YORK, Aug. 8, 2024 /PRNewswire/ -- Lucid
Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or
the "Company") a commercial-stage, cancer prevention medical
diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM),
today announced the successful completion of a #CheckYourFoodTube
Precancer Testing Event in partnership with the Fort Worth Fire Department (FWFD) and Front
Line Mobile Health ("Front Line"), a comprehensive medical
care provider for first responders. This was Lucid's first major
directly-contracted #CheckYourFoodTube event.
Front Line contracted with Lucid to hold this event, where
nearly 200 firefighters, deemed to be at risk for esophageal
precancer, underwent testing using Lucid's EsoGuard®
Esophageal DNA test at the FWFD training facility. Front Line staff
worked closely with Lucid clinical personnel and Fort Worth surgeon Dr. Adam Smith to facilitate on-site esophageal cell
collection using Lucid's EsoCheck® Esophageal Cell
Collection Device.
"Hosting this esophageal precancer testing event is an important
step in our commitment to the health and safety of our
firefighters," said FWFD Fire Chief Jim
Davis. "Having experienced the loss of my own father to
esophageal cancer, the critical nature of early detection of
esophageal precancer hits extremely close to home for me. I am a
huge proponent of EsoGuard and its ability to help ensure that our
team members can continue to effectively serve our community."
"We commend Chief Davis and Dr. Smith for demonstrating their
commitment to the health and safety of first responders who risk
their lives to serve their community, and for partnering with us on
a highly successful event," said Shaun
O'Neil, Lucid's President and Chief Operating Officer. "We
look forward to collaborating with Front Line on additional events
with other clients. We believe that directly contracting with
self-insured entities, including employers, unions, and municipal
departments, as well as medical care providers who service them,
will meaningfully contribute to long-term revenue growth."
Local Dallas Fort Worth news
outlets FOX 4 KDFW News and WFAA 8 News, as well as the Fort Worth
Star-Telegram, were on-site to cover the testing event.
Firefighters have a 62% increased risk of developing esophageal
cancer, and a 39% increased risk of dying from the same, according
to the Firefighter Cancer Support Group.
To learn more about hosting a #CheckYourFoodTube Precancer
Testing Event, please
visit www.esoguard.com/request-an-event.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a
commercial-stage, cancer prevention medical diagnostics company,
and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on
the millions of patients with gastroesophageal reflux disease
(GERD), also known as chronic heartburn, who are at risk of
developing esophageal precancer and cancer. Lucid's
EsoGuard® Esophageal DNA Test, performed on samples
collected in a brief, noninvasive office procedure with its
EsoCheck® Esophageal Cell Collection Device, represent
the first and only commercially available tools designed with the
goal of preventing cancer and cancer deaths through widespread,
early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more
information about its parent company PAVmed, please visit
www.pavmed.com.
Forward-Looking Statements
This press release includes
forward-looking statements that involve risk and uncertainties.
Forward-looking statements are any statements that are not
historical facts. Such forward-looking statements, which are based
upon the current beliefs and expectations of Lucid's management,
are subject to risks and uncertainties, which could cause actual
results to differ from the forward-looking statements. Risks and
uncertainties that may cause such differences include, among other
things, volatility in the price of Lucid's common stock; general
economic and market conditions; the uncertainties inherent in
research and development, including the cost and time required to
advance Lucid's products to regulatory submission; whether
regulatory authorities will be satisfied with the design of and
results from Lucid's clinical and preclinical studies; whether and
when Lucid's products are cleared by regulatory authorities; market
acceptance of Lucid's products once cleared and commercialized;
Lucid's ability to raise additional funding as needed; and other
competitive developments. In addition, Lucid continues to monitor
the COVID-19 pandemic and the pandemic's impact on Lucid's
businesses. These factors are difficult or impossible to predict
accurately and many of them are beyond Lucid's control. In
addition, new risks and uncertainties may arise from time to time
and are difficult to predict. For a further list and description of
these and other important risks and uncertainties that may affect
Lucid's future operations, see Part I, Item 1A, "Risk Factors," in
Lucid's most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, as the same may be updated in
Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form
10-Q filed by Lucid Diagnostics after its most recent Annual
Report. Lucid disclaims any intention or obligation to
publicly update or revise any forward-looking statement to reflect
any change in its expectations or in events, conditions, or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-holds-first-major-directly-contracted-esoguard-checkyourfoodtube-precancer-testing-event-302217686.html
SOURCE Lucid Diagnostics